This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Checkpoint with forkhead and ring finger domains (CHFR); DNA mismatch repair protein Mlh1 (MLH1)	<p>Studies in patient tissue samples and in mice suggest that <i>CHFR</i> and <i>MLH1</i> could help guide selection of anticancer therapy. Samples of human colon cancers with deficient DNA mismatch repair showed significantly lower CHFR expression than cancer samples that had stable mismatch repair ($p < 0.001$). In mice, loss of <i>Chfr</i> and <i>Mlh1</i> caused additive increases in cancer-associated mortality compared with expression <i>Chfr</i> and <i>Mlh1</i>. Next steps include evaluating the use of microtubule destabilizers in human colon cancer cell lines.</p> <p>SciBX 2(33); doi:10.1038/scibx.2009.1270 Published online Aug. 27, 2009</p>	Patent and licensing status undisclosed	<p>Fu, Z. <i>et al. J. Clin. Invest.</i>; published online Aug. 17, 2009; doi:10.1172/JCI37405</p> <p>Contact: Donald James Tindall, Mayo Clinic College of Medicine, Rochester, Minn. e-mail: tindall.donald@mayo.edu</p> <p>Contact: Zheng Fu, same affiliation as above e-mail: fu.zheng@mayo.edu</p> <p>Contact: Junjie Chen, The University of Texas M.D. Anderson Cancer Center, Houston, Texas e-mail: jchen8@mdanderson.org</p>